Litwin MS, Hays RD, Fink A, et al. The UCLA Prostate Cancer Index: Development, reliability, and validity of a health-related quality of life measure. Med Care 1998;36:1002-12.
Wei J, Dunn RL. Litwin MS, Sandler HM, Sanda MS. Development and Validation of the Expanded Prostate Cancer Index Composite (EPIC) for Comprehensive Assessment of Health-Related Quality of Life in Men with Prostate Cancer. Urology 2000;56:899-905.
EuroQol Group. A new facility for the measurement of health related quality of life. Health Policy 1990;16:199-208.
Torrance GW, Furlong W, Feeny D, Boyle M. Multi-attribute preference functions: Health Utilities Index. PharmacoEconomics 1995;7:503-20.
Krahn M, Ritvo P, Irvine J, et al. Construction of the Patient-Oriented Prostate Utility Scale (PORPUS): a multiattribute health state classification system for prostate cancer. J Clin Epidemiol 2000;53:920-30.
Froberg DG, Kane RL. Methodology for measuring health-state preferences-II: scaling methods. J Clin Epidemiol 1989;42:459-71.
Bremner KE, Tomlinson G, Krahn MD. Marker states and a health state prompt provide modest improvements in the reliability and validity of the standard gamble and rating scale in prostate cancer patients. Qual Life Res 2007;16:1665-75.
Torrance G, Feeny DH, Furlong WJ, Barr RD, Zhang Y, Wang Q. Multi-attribute preference functions for a comprehensive health state classification system: Health Utilities Index Mark 2. Med Care 1996;34:702-22.
Ritvo P, Irvine J, Naglie G, et al. Reliability and validity of the PORPUS, a combined psychometric and utility-based quality-of-life instrument for prostate cancer. J Clin Epidemiol 2005;58:466-74.
Krahn M, Bremner KE, Tomlinson G, Ritvo P, Irvine J, Naglie G. Responsiveness of disease-specific and generic utility instruments in prostate cancer patients. Qual Life Res 2007;16:509-22.
Krahn MD, Ritvo P, Irvine J, et al. Patient and community preferences for outcomes in prostate cancer: Implications for clinical policy. Med Care 2003;41:153-64.
Joly F, Alibhai SM, Galica J, et al. Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer. J Urol 2006;176:2443-7.
Krahn MD, Bremner KE, Tomlinson G, Naglie G. Utility and health-related quality of life in prostate cancer patients twelve months following radical prostatectomy or radiation therapy. Prostate Cancer and Prostatic Diseases 2009;12:4:361-368.
Matthew AG, Currie KL, Irvine J, et al. Serial personal digital assistant data capture of health-related quality of life: a randomized controlled trial in a prostate cancer clinic. Health & Quality of Life Outcomes 2007;5:38.
Krahn M.D. BK, Tomlinson G, Alibhai SMH, Laporte A, Naglie G. Effect of age on preferences for health outcomes in prostate cancer. Presented as a poster at the American Society of Clinical Oncology, Prostate Cancer Symposium, February 22-24, 2007, Orlando, Florida
Bremner KE, Carcone SM, Kowgier ME, et al. Clinical and demographic predictors of quality of life in prostate cancer survivors. Value in Health 2008;11:A73.
Kilbridge KL, Fraser G, Krahn M, et al. Lack of comprehension of common prostate cancer terms in an underserved population. J Clin Oncol 2009;27:2015-21.
Waldmann A, Rohde V, Bremner K, Krahn M, Kuechler T, Katalinic A. Measuring prostate-specific quality of life in prostate cancer patients scheduled for radiotherapy or radical prostatectomy and reference men in Germany and Canada using the Patient Oriented Prostate Utility Scale-Psychometric (PORPUS-P). BMC Cancer 2009;9:295.
Development and validation of a utility weighting function for the PORPUS- Patient Oriented Prostate Utility Scale Tomlinson G, Bremner KE, Ritvo P, Naglie G, Krahn MD. Medical Decision Making, published online 8 June 2011 DOI: 10.1177/0272989X11407203
The information contained
in this web site is intended for educational use only. It should
not be used to diagnose or treat illness. Nor should it replace
the advice of your physician. [contact